A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

• Status: Completed
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Constellation Pharmaceuticals
• Collaborator: The Leukemia and Lymphoma Society

Criteria

Inclusion Criteria:

• Adults (aged ≥ 18 years)

• Histologically or cytologically confirmed diagnosis of multiple myeloma that has progressed despite at least one line of standard therapy

• Must have measurable disease, defined by one or more of following: (i) a serum M protein > 0.5 g/dl measured by serum protein electrophoresis; (ii) urinary M protein excretion > 200 mg/24 hours; (iii) serum free light chain (FLC) measurement > 10 mg/dl, provided that the serum FLC ratio is abnormal

• Eastern Cooperative Oncology Group (ECOG) performance status ≤2

• Adequate hematological, renal, hepatic, and coagulation laboratory assessments

• Written informed consent to participate in this study before the performance of any study-related procedure

Exclusion Criteria:

• Current infection with HIV, Hepatitis B or Hepatitis C

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1

• Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

• Acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug

• Serum cardiac troponin (cTn) level ≥ 99% percentile of the upper reference limit

• QTcF > 470 msec on the screening ECG

• Left ventricular ejection fraction (LVEF) < 50%

• Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded.)

• Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection)

• Systemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of CPI-0610

• Treatment with an investigational small molecule less than 2 weeks before the first dose of CPI-0610. In addition, the first dose of CPI-0610 should not occur before a period equal to or greater than 5 half-lives of the small molecule investigational agent has elapsed

• Treatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-0610. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of CPI-0610 may be permitted in patients with rapidly progressive myeloma, following discussion with the medical monitor

• Treatment with medications that are known to be strong inhibitors or inducers of CYP450 enzymes

• Treatment with medications that are known to carry a risk of Torsades de Pointes

• Immunosuppressive treatment that cannot be discontinued both prior to study entry and for the duration of the study. Oral prednisone at a dose of 10 mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowed

• Pregnant or lactating women

• Women of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter

• Patients unwilling or unable to comply with the study protocol